Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01)

Metastatic Breast ◽

Phase Iii ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

A randomized, open-label, Phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab and chemotherapy: the Japan Breast Cancer Research Group-M05 PRECIOUS study

Japanese Journal of Clinical Oncology ◽

10.1093/jjco/hyy097 ◽

2018 ◽

Vol 48 (9) ◽

pp. 855-859 ◽

Cited By ~ 2

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Takayuki Ueno ◽

Naruto Taira ◽

Masahiro Kashiwaba ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

A randomised two-arm, prospective, multi-centre, open-label phase III trial comparing the activity and safety of a weekly versus a three-weekly paclitaxel treatment schedule in patients with advanced or metastatic breast cancer

http://isrctn.org/> ◽

10.1186/isrctn52817670 ◽

2012 ◽

Author(s):

M Verrill

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Weekly Paclitaxel ◽

Treatment Schedule ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Paclitaxel Treatment

Abstract PD3-11: A randomized, open-label, phase III trial of pertuzumab re-treatment in HER2-positive, locally advanced/metastatic breast cancer patients previously treated with pertuzumab, trastuzumab, and chemotherapy: The Japan Breast Cancer Research Group-M05 (PRECIOUS) study

10.1158/1538-7445.sabcs20-pd3-11 ◽

2021 ◽

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Taira Naruto ◽

Norikazu Masuda ◽

Masato Takahashi ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

PRECIOUS: A randomized, open-label phase III trial of pertuzumab retreatment in HER2-positive locally advanced/metastatic breast cancer patients who were previously treated with pertuzumab, trastuzumab, and chemotherapy.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.tps636 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. TPS636-TPS636

Author(s):

Yutaka Yamamoto ◽

Hiroji Iwata ◽

Takayuki Ueno ◽

Masahiro Kashiwaba ◽

Naruto Taira ◽

...

Keyword(s):

Breast Cancer ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Breast Cancer Patients ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Open Label Phase ◽

Abstract S6-6: A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

10.1158/0008-5472.sabcs12-s6-6 ◽

2012 ◽

Cited By ~ 24

Author(s):

PA Kaufman ◽

A Awada ◽

C Twelves ◽

L Yelle ◽

EA Perez ◽

...

Keyword(s):

Breast Cancer ◽

Multicenter Study ◽

Locally Advanced ◽

Metastatic Breast ◽

Phase Iii ◽

Open Label ◽

Eribulin Mesylate ◽

PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + Anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

Annals of Oncology ◽

10.1093/annonc/mdy272.357 ◽

2018 ◽

Vol 29 ◽

pp. viii121 ◽

Cited By ~ 1

Author(s):

S. Loibl ◽

O. Metzger ◽

S.J. Mandrekar ◽

C. Mundhenke ◽

S. Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

Abstract LB-177: First-line bevacizumab (BEV) + chemotherapy for hormone receptor-positive metastatic breast cancer (mBC): Subgroup analysis of the open-label non-inferiority TURANDOT phase III trial.

10.1158/1538-7445.am2013-lb-177 ◽

2013 ◽

Author(s):

Zsuzsanna Kahán ◽

Lubos Petruzelka ◽

Alexandru Eniu ◽

Rodica Anghel ◽

Krassimir Koynov ◽

...

Keyword(s):

Breast Cancer ◽

Subgroup Analysis ◽

Hormone Receptor ◽

Metastatic Breast ◽

Phase Iii ◽

First Line ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive

Abstract OT3-1-08: The PROCEED trial KCSG BR11-01: Phase III multicenter randomized open label study of irinotecan plus capecitabine versus capecitabine in patients previously treated with anthracycline and taxane for HER2 negative metastatic breast cancer

10.1158/0008-5472.sabcs13-ot3-1-08 ◽

2013 ◽

Author(s):

IH Park ◽

KS Lee ◽

S-A Im ◽

KH Jung ◽

KH Park ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Open Label ◽

Open Label Study ◽

Label Study ◽

Abstract OT3-02-07: PATINA: A randomized, open label, phase III trial to evaluate the efficacy and safety of palbociclib + anti-HER2 therapy + endocrine therapy (ET) vs. anti-HER2 therapy + ET after induction treatment for hormone receptor positive (HR+)/HER2-positive metastatic breast cancer (MBC)

10.1158/1538-7445.sabcs18-ot3-02-07 ◽

2019 ◽

Author(s):

O Metzger ◽

S Mandrekar ◽

S Loibl ◽

C Mundhenke ◽

S Seiler ◽

...

Keyword(s):

Breast Cancer ◽

Metastatic Breast ◽

Phase Iii ◽

Induction Treatment ◽

Efficacy And Safety ◽

Her2 Positive ◽

Open Label ◽

Phase Iii Trial ◽

Hormone Receptor Positive ◽

Open Label Phase

Overall survival analysis of a randomized phase III trial comparing nab-paclitaxel with solvent-based paclitaxel in patients with metastatic breast cancer previously treated with anthracycline

European Journal of Cancer Supplements ◽

10.1016/s1359-6349(08)70885-1 ◽

2008 ◽

Vol 6 (7) ◽

pp. 218 ◽

Cited By ~ 2

Author(s):

N. Davidson ◽

S. Tjulandin ◽

J. O'Shaughnessy ◽

P. Bhar ◽

W. Gradishar

Keyword(s):

Breast Cancer ◽

Overall Survival ◽

Survival Analysis ◽

Metastatic Breast ◽

Phase Iii ◽

Phase Iii Trial ◽

Previously Treated ◽

Overall Survival Analysis